biotech

How the Ultragenyx Hype Went From a Very Promising to a 52-Week Low

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), which targets rare and ultra-rare genetic diseases, is finding itself in a "rare" situation of its own. The biotech outfit just hit a 52-week low. ...
Read Full Story »

Intra-Cellular Soars on Critical FDA Update

Intra-Cellular Therapies Inc. (NASDAQ: ITCI) saw an incredible gain in its shares early on Wednesday after the U.S. Food and Drug Administration (FDA) gave a positive regulatory update on the ...
Read Full Story »

Krystal Biotech Files for IPO

Krystal Biotech has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No conclusive pricing details were mentioned in the filing; ...
Read Full Story »

Analysts Say Sienna Biopharmaceuticals Stock Could Run 50% to 100%

The quiet period for Sienna Biopharmaceuticals, Inc. (NASDAQ: SNNA) is over after its initial public offering. The Westlake Village, California-based company recently sold just 4,983,333 shares of common stock at ...
Read Full Story »

Coherus Bio Jumps on Private Placement

Coherus Biosciences, Inc. (NASDAQ: CHRS) saw its shares jump on Monday after the company announced that it plans to raise up to $150 million in a two tranche private placement. ...
Read Full Story »

FibroGen Prices Follow-On Offering

Shares of FibroGen Inc. (NASDAQ: FGEN) saw a handy gain on Wednesday after the firm announced the pricing of its underwritten follow-on offering. The offering is expected to close by ...
Read Full Story »

Zai Lab Files for IPO

Zai Lab has registered an F-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). No pricing details were given in the filing, but ...
Read Full Story »

How Kala Pharmaceuticals Could Rise 100% to 200%

Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is a recent initial public offering that could come blessed with magical upside if its possibilities blossom into a positive reality. The company is targeting ...
Read Full Story »

Major Biotechs Send Short Sellers Running for Cover

The short interest data are out for the most recent settlement date, July 31. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Why Fibrogen Shares Are Exploding

When FibroGen Inc. (NASDAQ: FGEN) released its most recent quarterly results after the markets closed on Monday, it was not the most important news that broke. The firm also updated ...
Read Full Story »

Jefferies Sees Big Upside From 4 Upcoming Near-Term Biotech Catalysts

If there is one area that can generate riches for speculative investors, it would have to be biotech and emerging pharma. After all, how many companies can go from nothing ...
Read Full Story »

Agile Therapeutics Tanks on Secondary Offering

Agile Therapeutics Inc. (NASDAQ: AGRX) saw its stock dip early on Thursday after the firm announced a secondary offering. Although the stock is down year to date, it’s actually more ...
Read Full Story »

Zealand Pharma Closes in on IPO

Zealand Pharma has filed an amended F-1 form with the U.S. Securities and Exchange Commission (SEC) in regards to its initial public offering (IPO). The company intends to price its ...
Read Full Story »

AbbVie Slips Despite Q2 Earnings Beat

AbbVie Inc. (NYSE: ABBV) reported its second-quarter financial results before the markets opened on Friday. The biotech giant posted $1.42 in earnings per share (EPS) and $6.94 billion in revenue, ...
Read Full Story »

Tetraphase Pharma Decides to Reap Profits With Secondary Offering

Tetraphase Pharmaceuticals Inc. (NASDAQ: TTPH) saw its shares pull back on Friday after the company announced that it has priced a secondary offering. Keep in mind that even though shares ...
Read Full Story »